Ehvidence

Real-time analysis of medical evidence

Pooled effects, number needed to treat, and number needed to harm across clinical topics — every metric recomputed from the underlying study data.

13
Topics
47
Studies
243,706
Patients

Current coverage: 13 clinical topics with real-time evidence analysis. Click a topic below to explore the underlying studies and computed pooled effects.

Efficacy across topics

Each point is a topic, positioned by pooled improvement on its primary outcome (y) and total patients analyzed (x). Color reflects evidence status. Click a point to open the topic.

0%25%50%75%100%1001k10k100kPatients (log scale)Improvement %Beta-carotene for skin cancer preventionCelecoxib for skin cancer preventionCoQ10 in Chronic Heart Failure (Q-SYMBIO)Nicotinamide for skin cancer preventionOmega-3 (fish oil) for cardiovascular eventsOral retinol for skin cancer preventionOral / subcutaneous vs intravenous opioidsStatins for primary preventionS. boulardii for pediatric acute diarrhea (China)Statins for secondary preventionSunscreen for skin cancer preventionTopical 5-fluorouracil for skin cancer preventionVitamin K prophylaxis for newborns

All topics

Topic Primary outcome RR [95% CI] Improvement NNT Studies Patients Status
Efficacy (RCT)
CoQ10 in Chronic Heart Failure (Q-SYMBIO) Cardiology Major Adverse Cardiovascular Events (MACE) 0.57 [0.38–0.85] 43% 9 1 420 Limited data
Statins for primary prevention Cardiovascular Major cardiovascular events 0.66 [0.60–0.73] 34% 65 7 61,844 Favorable
Statins for secondary prevention Cardiovascular Major cardiovascular events 0.76 [0.72–0.80] 24% 17 4 38,153 Favorable
Omega-3 (fish oil) for cardiovascular events Cardiovascular Major cardiovascular events 0.86 [0.78–0.95] 14% 68 7 93,805 Favorable
Vitamin K prophylaxis for newborns Neonatal Early clinical bleeding 0.18 [0.10–0.34] 82% 16 5 3,926 Favorable
S. boulardii for pediatric acute diarrhea (China) Pediatric gastroenterology Total effectiveness 1.20 [1.15–1.26] 20% 7 10 1,062 Favorable
Topical 5-fluorouracil for skin cancer prevention Skin cancer prevention Squamous-cell carcinoma (needing surgery) 0.25 [0.09–0.65] 75% 31 1 932 Favorable
Celecoxib for skin cancer prevention Skin cancer prevention Nonmelanoma skin cancer 0.43 [0.24–0.76] 57% 6 1 240 Favorable
Sunscreen for skin cancer prevention Skin cancer prevention Squamous-cell carcinoma 0.61 [0.46–0.81] 39% — 3 4,863 Favorable
Oral retinol for skin cancer prevention Skin cancer prevention Squamous-cell carcinoma 0.74 [0.56–0.98] 26% — 1 2,297 Favorable
Nicotinamide for skin cancer prevention Skin cancer prevention New nonmelanoma skin cancers 0.77 [0.62–0.96] 23% 2 1 386 Favorable
Beta-carotene for skin cancer prevention Skin cancer prevention Nonmelanoma skin cancer 1.05 [0.91–1.22] -5% — 1 1,805 Inconclusive
Implementation / QI
Oral / subcutaneous vs intravenous opioids Opioid stewardship IV opioid exposure 0.20 [0.12–0.35] 80% — 5 33,973 Favorable

Recent studies